Evidence map›Paper›PMID 34410635›Full record

Trial reportInternational journal of hematology2021

Carfilzomib, dexamethasone, and daratumumab in Asian patients with relapsed or refractory multiple myeloma: post hoc subgroup analysis of the phase 3 CANDOR trial.

Kenshi Suzuki, Chang-Ki Min, Kihyun Kim, Je-Jung Lee, Hirohiko Shibayama, Po-Shen Ko, Shang-Yi Huang, Sin-Syue Li, Bifeng Ding, Monica Khurana and 1 more

Registry-linked trialAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03158688 (A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03158688 phase3completednot on this map

A Randomized, Open-label, Phase 3 Study Comparing Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

TypeinterventionalSponsorAmgenRan2017 to 2022Enrolled466ConditionsRelapsed Multiple Myeloma, Refractory Multiple MyelomaArmsDexamethasone, Daratumumab, Carfilzomib
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 10 institutions in 4 countries.

Kenshi SuzukiDepartment of Hematology, Japanese Red Cross Medical Center, 4-1-22 Hiroo, Shibuya-ku, Tokyo, Japan. ken-suzuki@mtb.biglobe.ne.jp.ORCID http://orcid.org/0000-0001-7132-5337
Chang-Ki MinDivision of Hematology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
Kihyun KimDivision of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Je-Jung LeeDepartment of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University Medical School, Hwasun, Jeollanam-do, South Korea.
Hirohiko ShibayamaDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
Po-Shen KoFaculty of Medicine, National Yang-Ming University, Taipei City, Taiwan.
Shang-Yi HuangDivision of Hematology, Department of Internal Medicine, National Taiwan University, Taipei City, Taiwan.
Sin-Syue LiDivision of Hematology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Bifeng DingAmgen Inc., Thousand Oaks, CA, USA.
Monica KhuranaAmgen Inc., Thousand Oaks, CA, USA.
Shinsuke IidaDepartment of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Amgen (United States) · USChonnam National University Hwasun Hospital · KRJapanese Red Cross Medical Center · JPNagoya City University · JPNational Cheng Kung University Hospital · TWNational Taiwan University · TWNational Yang Ming Chiao Tung University · TWSamsung Medical Center · KRThe Catholic University of Korea Seoul St. Mary's Hospital · KRThe University of Osaka · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDue to increasing use of frontline lenalidomide, effective and safe lenalidomide-free therapies for relapsed/refractory multiple myeloma (RRMM) are needed in Asia. This subgroup analysis of phase 3 CANDOR study evaluated efficacy and safety of KdD vs Kd in Asian patients with RRMM.

methodsSelf-identified Asian patients with RRMM (KdD = 46; Kd = 20) with 1‒3 prior therapies were included. The primary endpoint of progression-free survival was estimated by stratified Cox regression.

resultsBaseline demographics and patient characteristics were balanced in both arms. KdD reduced the risk of progression or death by 25% vs Kd [hazard ratio (HR) = 0.75; 95% CI 0.259, 2.168] in the Asian subgroup, compared with 37% vs Kd (0.63; 0.464, 0.854) in the overall CANDOR population. Percentage of patients who reported grade ≥ 3 treatment-emergent adverse events (TEAEs) in the KdD and Kd arms was 95.7 and 90.0%, respectively. Serious AEs were observed in 58.7 and 40.0% of patients in the KdD and Kd arms, respectively. There were two (4.3%) fatal TEAEs in the KdD arm due to infections.

conclusionsThere was a trend toward better efficacy and a favorable benefit-risk profile for KdD vs Kd in Asian patients with RRMM. Cautious interpretation is warranted due to small patient size.

Indexed as

Asian PeopleAdultAgedAged, 80 and overAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneDrug Resistance, NeoplasmFemaleHumansMaleMiddle AgedMultiple MyelomaOligopeptidesPrognosisProportional Hazards ModelsAntibodies, MonoclonalcarfilzomibdaratumumabDexamethasoneOligopeptidesAsian populationCANDOR trialCarfilzomibDaratumumabRelapsed refractory multiple myeloma

Identifiers

PMID34410635
OpenAlexW3195507064

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.